Key Mesenchymal Precursor Cell Patents Granted in United States and China

Key Mesenchymal Precursor Cell Patents Granted in United States and China

New Granted Claims Confer Exclusive, Long-Term Commercial Rights in the
World's Largest Established and Emerging Healthcare Markets

MELBOURNE, Australia, Feb. 6, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine
company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has
been granted three key new patents by the United States Patent and Trade Mark
Office (USPTO) and the State Intellectual Property Office of the People's
Republic of China. These patents deliver major commercial advantages and offer
long term protection in these territories for the company's products based on
its proprietary Mesenchymal Precursor Cell (MPC) adult stem cell technology

In the United States, USPTO patent 8,367,405 confers Mesoblast with exclusive
rights through to March 2029 to compositions-of-matter covering its current
products.This patent extends by more than seven years Mesoblast's exclusive
commercial rights in the United States,the world's largest healthcare
market,toMPC compositions-of-matter beyond those rights already conferred by
USPTO patents 7,122,178 and8,158,118 whose expiry had previously been
extended toNovember 2021.

In China, patents CN200580040212.1 and CN200580039970.1provide Mesoblast with
exclusive MPC product commercial rights and protection through to 2025. These
patents provide Mesoblast with long-term composition-of-matter protection for
the company's MPC products derived from an unlimited range of tissue sources,
such as bone marrow, adipose tissue, placenta, umbilical cord, and dental
pulp. These Chinese patents underpin Mesoblast's corporate strategy to
targetthe world's largest emerging market for regenerative medicines, andto
protect its manufacturing processes and know-how.

Mesoblast Limited

Mesoblast Limited is a world leader in the development of biologic products
for the broad field of regenerative medicine. Mesoblast's patented Mesenchymal
Precursor Cell (MPC) technology is being developed for a broad range of major
clinical diseases, including inflammatory and immunologic conditions, diabetes
and its complications, orthopedic spine conditions, and cardiovascular

CONTACT: Julie Meldrum
         Global Head of Corporate Communications
         T: +61 3 9639 6036
Press spacebar to pause and continue. Press esc to stop.